Writing
Notes from the work.
Paul Albarrán writes about contracts, regulators and growing companies, for the founders who run them.
503A or 503B? Choosing a compounding partner for telehealth
How federal law divides compounding between 503A pharmacies and 503B outsourcing facilities, and what that means for a health brand’s supply contracts.
BPC-157 and compounded peptides: FDA’s 2026 actions
FDA’s interim peptide policy is still under review. What the record shows on BPC-157 and six other peptides: the reported votes, FDA’s briefing and its letters.
The DEA telemedicine cliff: what ends December 31, 2026
DEA’s temporary telemedicine rule ends December 31, 2026. What ends, which rules stay in force, where the replacement stands, and what state law adds.
FTC v. Hims & Hers: health data, pixels and cancellation
What the FTC alleged against Hims & Hers in July 2026 about pixels, privacy and cancellation, the laws it cites, and where the click-to-cancel rule stands.
Does a telehealth company need LegitScript certification?
What LegitScript certification is, why ad platforms and payment processors ask for it, and how telehealth and pharmacy companies can prepare to apply.
Compounded drug claims FDA has flagged in telehealth ads
What FDA has told telehealth companies not to claim about compounded drugs, what its 2025 and 2026 warning letters alleged, and the law the letters cite.
Do the 2026 pharma tariffs reach compounding APIs?
What the 2026 Section 232 pharmaceutical tariffs cover, their rates and dates, and why the text leaves bulk API for compounding a patented molecule open.
Texting customers: TCPA rules for health brands
How the Telephone Consumer Protection Act reaches marketing calls and texts, and the consent, do-not-call and vendor practices that limit exposure.
The information on this site is general information, not legal advice.
Start with the real thing.
Bring Paul the contract or the question keeping a decision stuck. A short note is enough.